Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LSZ 102 |
| Synonyms | |
| Therapy Description |
LSZ 102 is a selective estrogen receptor degrader (SERD) that prevents cell proliferation of ER-positive cells (PMID: 29562737). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LSZ 102 | LSZ102|LSZ-102 | Hormone - Anti-estrogens 31 | LSZ 102 is a selective estrogen receptor degrader (SERD) that prevents cell proliferation of ER-positive cells (PMID: 29562737). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02734615 | Phase I | Alpelisib + LSZ 102 LSZ 102 + Ribociclib LSZ 102 | Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers | Terminated | USA | ITA | FRA | DEU | BEL | 2 |